- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
Patent holdings for IPC class A61P 7/12
Total number of patents in this class: 189
10-year publication summary
|
4
|
9
|
4
|
6
|
9
|
5
|
9
|
8
|
7
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Chinook Therapeutics, Inc. | 39 |
11 |
| Novo Nordisk A/S | 2281 |
5 |
| Nippon Chemiphar Co., Ltd. | 232 |
4 |
| Merck Sharp & Dohme LLC | 3732 |
4 |
| Boehringer Ingelheim International GmbH | 4637 |
3 |
| The General Hospital Corporation | 4797 |
3 |
| Takeda Pharmaceutical Company Limited | 2716 |
3 |
| Wellesley Pharmaceuticals, LLC | 23 |
3 |
| Bristol-myers Squibb Company | 4824 |
2 |
| The Regents of the University of California | 20268 |
2 |
| The Board of Trustees of the Leland Stanford Junior University | 6526 |
2 |
| Kao Corporation | 5001 |
2 |
| Abbvie Inc. | 1814 |
2 |
| Vertex Pharmaceuticals Incorporated | 1621 |
2 |
| AmideBio, LLC | 15 |
2 |
| Astellas Pharma Inc. | 1053 |
2 |
| Betta Pharmaceuticals Co., Ltd. | 181 |
2 |
| Cancer Research Technology Limited | 524 |
2 |
| Daiichi Sankyo Company, Limited | 1880 |
2 |
| Eli Lilly and Company | 3911 |
2 |
| Other owners | 129 |